[go: up one dir, main page]

PE20170949A1 - Espiroindolinas para el tratamiento y profilaxis de infeccion por virus respiratorio sincitial (rsv) - Google Patents

Espiroindolinas para el tratamiento y profilaxis de infeccion por virus respiratorio sincitial (rsv)

Info

Publication number
PE20170949A1
PE20170949A1 PE2017000576A PE2017000576A PE20170949A1 PE 20170949 A1 PE20170949 A1 PE 20170949A1 PE 2017000576 A PE2017000576 A PE 2017000576A PE 2017000576 A PE2017000576 A PE 2017000576A PE 20170949 A1 PE20170949 A1 PE 20170949A1
Authority
PE
Peru
Prior art keywords
rsv
treatment
spiroindolines
prophylaxis
infection
Prior art date
Application number
PE2017000576A
Other languages
English (en)
Inventor
Stuart Cockerill
Neil Mathews
Simon Ward
Graham Lunn
Michael Paradowski
Simorte Jose Miguel Gascon
Original Assignee
Reviral Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51946966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20170949(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Reviral Ltd filed Critical Reviral Ltd
Publication of PE20170949A1 publication Critical patent/PE20170949A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se refiere a un compuesto de formula I, donde: X e Y son cada N o C sustituido, y el otro es CH; L es un enlace sencillo, alquileno C1-C3, entre otros; R1 es alquilo C1-C6, alquenilo C2-C6, entre otros; Z es halo, haloalquilo C1-C6, entre otros; m es 0 o 1. Son compuestos preferidos: 1´-{[5-(aminometil)-1-(4,4,4-trifluorobutil)-1H-1,3-benzodiazol-2-il]metil}-6´-fluoro-1´,2´-dihidrospiro[ciclopropano-1,3´-indol]-2´-ona; 1´-((5-(aminometil)-1-(4,4,4-trifluorobutil)-1H-benzo[d]imidazol-2-il)metil)espiro-[ciclopropano-1,3´-pirrolo[2,3-b]-piridin]-2´-(1´H)-ona; entre otros. Tambien se refiere a una composicion farmaceutica. Dichos compuestos son inhibidores del virus respiratorio sincitial (RSV), siendo utiles en el tratamiento de infecciones causados por dicho virus
PE2017000576A 2014-10-07 2015-10-06 Espiroindolinas para el tratamiento y profilaxis de infeccion por virus respiratorio sincitial (rsv) PE20170949A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1417707.5A GB201417707D0 (en) 2014-10-07 2014-10-07 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
PE20170949A1 true PE20170949A1 (es) 2017-07-13

Family

ID=51946966

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000576A PE20170949A1 (es) 2014-10-07 2015-10-06 Espiroindolinas para el tratamiento y profilaxis de infeccion por virus respiratorio sincitial (rsv)

Country Status (31)

Country Link
US (1) US10106539B2 (es)
EP (1) EP3204375B1 (es)
JP (1) JP6695334B2 (es)
KR (2) KR102561796B1 (es)
CN (1) CN107108557B (es)
AR (1) AR102181A1 (es)
AU (1) AU2015329778B2 (es)
BR (1) BR112017007311B1 (es)
CA (1) CA2963740C (es)
CL (1) CL2017000839A1 (es)
CO (1) CO2017004603A2 (es)
CY (1) CY1121564T1 (es)
DK (1) DK3204375T3 (es)
ES (1) ES2718976T3 (es)
GB (1) GB201417707D0 (es)
HR (1) HRP20190808T1 (es)
HU (1) HUE043553T2 (es)
LT (1) LT3204375T (es)
MX (1) MX373233B (es)
NZ (1) NZ731323A (es)
PE (1) PE20170949A1 (es)
PL (1) PL3204375T3 (es)
PT (1) PT3204375T (es)
RS (1) RS58706B1 (es)
RU (1) RU2734248C2 (es)
SG (1) SG11201702766YA (es)
SI (1) SI3204375T1 (es)
SM (1) SMT201900249T1 (es)
TR (1) TR201903362T4 (es)
TW (1) TWI718107B (es)
WO (1) WO2016055780A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016197908A1 (zh) 2015-06-08 2016-12-15 南京明德新药研发股份有限公司 咪唑衍生物及其中间体的制备方法和晶型
ES2878058T3 (es) * 2016-08-04 2021-11-18 Reviral Ltd Derivados de pirimidina y su uso en el tratamiento y la prevención de una infección por virus respiratorio sincitial
GB201711704D0 (en) * 2017-07-20 2017-09-06 Reviral Ltd Pharmaceutical compounds
GB201721812D0 (en) * 2017-12-22 2018-02-07 Reviral Ltd Pharmaceutical compounds
CN116077494A (zh) * 2023-01-11 2023-05-09 黑龙江中医药大学 一种治疗呼吸道合胞病毒的药物组合物及其制备方法
WO2024174953A1 (zh) * 2023-02-21 2024-08-29 苏州隆博泰药业有限公司 苯并咪唑类衍生物及其医药用途
WO2024252355A1 (en) 2023-06-08 2024-12-12 Pfizer Inc. Pediatric dosing regimens comprising a fusion inhibitor for the treatment of rsv
WO2025120500A1 (en) 2023-12-06 2025-06-12 Pfizer Inc. Benzodiazepine compounds as n-protein inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57102863A (en) * 1980-12-16 1982-06-26 Takeda Chem Ind Ltd Spiroindolinone and its preparation
PL194216B1 (pl) * 1998-01-23 2007-05-31 Sankyo Co Pochodne spiropiperydyny, lekarstwo oraz środek zapobiegawczy lub terapeutyczny zawierające jako składnik czynny te pochodne i zastosowanie pochodnych spiropiperydyny
DE60013836T2 (de) * 1999-06-28 2006-01-19 Janssen Pharmaceutica N.V. Replikationsinhibitoren des respiratorischen synzytialvirus
US6774134B2 (en) * 2000-12-20 2004-08-10 Bristol-Myers Squibb Company Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
US6919331B2 (en) 2001-12-10 2005-07-19 Bristol-Myers Squibb Company Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
US7205328B2 (en) * 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
MX2007004393A (es) 2004-10-13 2007-04-25 Merck & Co Inc Antagonistas del receptor a peptido relacionado con el gen calcitonina.
WO2010103306A1 (en) 2009-03-10 2010-09-16 Astrazeneca Uk Limited Benzimidazole derivatives and their use as antivaral agents
GB201119538D0 (en) * 2011-11-10 2011-12-21 Viral Ltd Pharmaceutical compounds
PE20150723A1 (es) 2012-10-16 2015-05-15 Janssen Sciences Ireland Uc Compuestos antiviricos para el vsr
KR20160007629A (ko) * 2013-05-14 2016-01-20 에프. 호프만-라 로슈 아게 호흡기 세포융합 바이러스 감염의 치료 및 예방을 위한 아자-옥소-인돌
CN105392787B (zh) * 2013-05-14 2017-11-24 豪夫迈·罗氏有限公司 用于治疗和预防呼吸道合胞病毒感染的氮杂‑氧代‑吲哚
WO2014184163A1 (en) * 2013-05-14 2014-11-20 F. Hoffmann-La Roche Ag Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
BR112016002638A2 (pt) 2013-08-12 2017-08-01 Hoffmann La Roche novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório
KR20160030271A (ko) * 2013-08-12 2016-03-16 에프. 호프만-라 로슈 아게 호흡기 세포융합 바이러스 감염의 치료 및 예방을 위한 아자-옥소-인돌
CN105408330A (zh) * 2013-08-12 2016-03-16 豪夫迈·罗氏有限公司 新的用于治疗和预防呼吸道合胞病毒感染的氮杂-氧代-吲哚
CN105431419A (zh) * 2013-08-15 2016-03-23 豪夫迈·罗氏有限公司 新的用于治疗和预防呼吸道合胞病毒感染的氮杂-氧代-吲哚
HK1222855A1 (zh) 2013-08-15 2017-07-14 F. Hoffmann-La Roche Ag 新的用於治疗和预防呼吸道合胞病毒感染的氮杂-氧代-吲哚
KR20160030569A (ko) * 2013-08-15 2016-03-18 에프. 호프만-라 로슈 아게 호흡기 세포융합 바이러스 감염의 치료 및 예방을 위한 신규한 아자-옥소-인돌

Also Published As

Publication number Publication date
LT3204375T (lt) 2019-05-10
SI3204375T1 (sl) 2019-05-31
DK3204375T3 (en) 2019-04-01
CA2963740A1 (en) 2016-04-14
MX373233B (es) 2020-05-08
RU2017113026A (ru) 2018-11-13
KR20230116097A (ko) 2023-08-03
PT3204375T (pt) 2019-04-01
RU2017113026A3 (es) 2019-03-22
CN107108557B (zh) 2020-11-10
TWI718107B (zh) 2021-02-11
RS58706B1 (sr) 2019-06-28
CL2017000839A1 (es) 2017-10-13
GB201417707D0 (en) 2014-11-19
SMT201900249T1 (it) 2019-07-11
PL3204375T3 (pl) 2019-06-28
JP6695334B2 (ja) 2020-05-20
EP3204375A1 (en) 2017-08-16
EP3204375B1 (en) 2019-02-13
HRP20190808T1 (hr) 2019-08-23
ES2718976T3 (es) 2019-07-05
HUE043553T2 (hu) 2019-09-30
CN107108557A (zh) 2017-08-29
BR112017007311B1 (pt) 2022-11-22
AR102181A1 (es) 2017-02-08
MX2017004425A (es) 2017-10-11
AU2015329778A8 (en) 2017-05-18
JP2017530992A (ja) 2017-10-19
US10106539B2 (en) 2018-10-23
TR201903362T4 (tr) 2019-04-22
WO2016055780A1 (en) 2016-04-14
NZ731323A (en) 2022-09-30
KR102561796B1 (ko) 2023-07-31
AU2015329778A1 (en) 2017-05-04
TW201625583A (zh) 2016-07-16
US20170305908A1 (en) 2017-10-26
CO2017004603A2 (es) 2017-10-31
CY1121564T1 (el) 2020-05-29
AU2015329778B2 (en) 2020-04-23
RU2734248C2 (ru) 2020-10-13
KR20170066577A (ko) 2017-06-14
CA2963740C (en) 2022-11-29
SG11201702766YA (en) 2017-05-30
BR112017007311A2 (pt) 2017-12-19

Similar Documents

Publication Publication Date Title
PE20170949A1 (es) Espiroindolinas para el tratamiento y profilaxis de infeccion por virus respiratorio sincitial (rsv)
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
DOP2017000149A (es) Compuestos de triazolopirimidina y usos de los mismos
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
PH12015502443A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
PH12017500252B1 (en) New spiro[3h-indole-3,2`-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
ECSP17002135A (es) Compuestos antiproliferativos y métodos de uso de los mismos
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
PE20161552A1 (es) Compuestos de dihidroisoquinolinona sustituida
BR112017001565A2 (pt) ?composto, métodos para tratar uma infecção e para fabricar um medicamento, composição farmacêutica, e, uso de um composto?
MA37712B1 (fr) Inhibiteurs macrocycliques de virus flaviviridae
SV2011003997A (es) Pirimidinas fusionadas
ECSP099461A (es) Compuesto heteromonocíclico y uso del mismo
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
PE20220281A1 (es) Compuestos de aza-benzotiofeno y aza-benzofurano como antihelminticos
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
PH12019501198A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MX375153B (es) Compuestos antihelminticos.
CL2009001044A1 (es) Compuestos cristalinos derivados de heterociclos puenteados por un alqueno; utiles en el tratamiento de enfermedades metabolicas, enfermedades circulatorias, enfermedades del snc, entre otras enfermedades.
SV2016005351A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
BR112017003242A2 (pt) composto, métodos para tratar infecção por vírus e para fabricação de um medicamento, composição farmacêutica, e, uso de um composto.
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
SV2017005381A (es) Compuestos de imidazopiridazina